{"schema_version":"1.0","type":"article","title":"After Ivonescimab's Rejection, Pfizer Is the One Testing Survival First","url":"https://drugnews.com.tw/articles/2026-11-19-pd1-vegf-challengers-evidence-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-19-pd1-vegf-challengers-evidence-en.md","lang":"en","date":"2026-11-19","publish_at":"2026-11-19T08:00:00+08:00","updated_at":"2026-11-19","category":"商業分析系列","topic":"商業分析系列","tags":["Lung cancer","PD-1/VEGF","Pfizer","BioNTech"],"summary":"The two global first-line NSCLC programs differ in OS endpoint status; deal size and local relevance cannot establish clinical eligibility or success.","key_points":["As registered on 2026-11-17, both specified global first-line NSCLC programs track OS: Pfizer makes it primary and BioNTech/BMS secondary; this establishes no efficacy or approval ranking.","Endpoints and populations define the comparison.","Contract ceilings differ from verified payments."],"facts":[{"claim":"Symbiotic-Lung-01 planned enrollment","value":1410,"unit":"participants","as_of":"2026-10-08","source":"https://clinicaltrials.gov/study/NCT07222566"},{"claim":"Symbiotic-Lung-01 estimated primary completion","value":"2029-02-27","unit":"date","as_of":"2026-10-08","source":"https://clinicaltrials.gov/study/NCT07222566"},{"claim":"ROSETTA Lung-02 planned enrollment","value":1580,"unit":"participants","as_of":"2026-11-02","source":"https://clinicaltrials.gov/study/NCT06712316"},{"claim":"MK-2010-002 planned enrollment","value":480,"unit":"participants","as_of":"2026-11-05","source":"https://clinicaltrials.gov/study/NCT07793942"},{"claim":"RC148 planned enrollment","value":574,"unit":"participants","as_of":"2026-07-14","source":"https://clinicaltrials.gov/study/NCT07416474"},{"claim":"AP505 planned enrollment","value":80,"unit":"participants","as_of":"2025-02-20","source":"https://clinicaltrials.gov/study/NCT06838546"},{"claim":"China second-line SCLC planned enrollment","value":404,"unit":"participants","as_of":"2026-10-22","source":"https://clinicaltrials.gov/study/NCT06616532"},{"claim":"China second-line SCLC estimated primary completion","value":"2027-05","unit":"month","as_of":"2026-10-22","source":"https://clinicaltrials.gov/study/NCT06616532"},{"claim":"ROSETTA Lung-01 planned enrollment","value":621,"unit":"participants","as_of":"2026-10-14","source":"https://clinicaltrials.gov/study/NCT06712355"},{"claim":"BNT327 upfront","value":1.5,"unit":"USD billion","as_of":"2025-06-02","source":"https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2025/BioNTech-BMS-Partnership-Presentation.pdf"},{"claim":"BNT327 anniversary payments","value":2,"unit":"USD billion","as_of":"2025-06-02","source":"https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2025/BioNTech-BMS-Partnership-Presentation.pdf"},{"claim":"BNT327 milestone ceiling","value":7.6,"unit":"USD billion","as_of":"2025-06-02","source":"https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2025/BioNTech-BMS-Partnership-Presentation.pdf"},{"claim":"BNT327 nominal payment ceiling","value":11.1,"unit":"USD billion","as_of":"2025-06-02","source":"https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2025/BioNTech-BMS-Partnership-Presentation.pdf"},{"claim":"Merck upfront","value":588,"unit":"USD million","as_of":"2024-11-14","source":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/"},{"claim":"Merck verified upfront plus technology transfer","value":888,"unit":"USD million","as_of":"2026-02-24","source":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm"},{"claim":"BMS verified upfront plus first anniversary payment","value":2,"unit":"USD billion","as_of":"2026-10-29","source":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm"},{"claim":"Pfizer upfront","value":1.25,"unit":"USD billion","as_of":"2025-05-19","source":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio"},{"claim":"Pfizer conditional milestone ceiling","value":4.8,"unit":"USD billion","as_of":"2025-05-19","source":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio"}],"sections":["01｜Pfizer puts the hardest question into the main test","02｜BioNTech's earlier result concerns different patients","03｜Merck has paid for admission; the main test is still ahead","04｜Taiwan's AP Biosciences takes another route","References"],"references":[{"title":"Ivonescimab BLA update","source":"Summit","date":"2026-11-15","url":"https://www.smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx?use_xbridge3=true"},{"title":"Symbiotic-Lung-01","source":"ClinicalTrials.gov","date":"2026-10-08","url":"https://clinicaltrials.gov/study/NCT07222566"},{"title":"ROSETTA Lung-02","source":"ClinicalTrials.gov","date":"2026-11-02","url":"https://clinicaltrials.gov/study/NCT06712316"},{"title":"MK-2010-002","source":"ClinicalTrials.gov","date":"2026-11-05","url":"https://clinicaltrials.gov/study/NCT07793942"},{"title":"RC148 first-line squamous NSCLC","source":"ClinicalTrials.gov","date":"2026-07-14","url":"https://clinicaltrials.gov/study/NCT07416474"},{"title":"B1962 colorectal phase IIb","source":"ClinicalTrials.gov","date":"2025-02-20","url":"https://clinicaltrials.gov/study/NCT06838546"},{"title":"PM8002 second-line SCLC","source":"ClinicalTrials.gov","date":"2026-10-22","url":"https://clinicaltrials.gov/study/NCT06616532"},{"title":"ROSETTA Lung-01","source":"ClinicalTrials.gov","date":"2026-10-14","url":"https://clinicaltrials.gov/study/NCT06712355"},{"title":"A Transformative Global Partnership for BNT327","source":"BMS / BioNTech","date":"2025-06-02","url":"https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2025/BioNTech-BMS-Partnership-Presentation.pdf"},{"title":"Pfizer enters 3SBio agreement","source":"Pfizer","date":"2025-05-19","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio"},{"title":"LM-299 global license","source":"Merck","date":"2024-11-14","url":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/"},{"title":"MK-2010 with sac-TMT","source":"ClinicalTrials.gov","date":"2026-10-15","url":"https://clinicaltrials.gov/study/NCT07785609"},{"title":"2025 Form 10-K","source":"Merck / SEC","date":"2026-02-24","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm"},{"title":"2026 Q3 Form 10-Q","source":"BMS / SEC","date":"2026-10-29","url":"https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm"},{"title":"2025 Q3 quarterly report","source":"BioNTech / SEC","date":"2025-11-03","url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm"},{"title":"Pfizer completes 3SBio license","source":"Pfizer","date":"2025-07-24","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio"},{"title":"AP505 amended out-licensing arrangement","source":"AP Biosciences","date":"2026-03-30","url":"https://www.apbioinc.com/en/news-detail67.htm"},{"title":"2026 Q3 quarterly report","source":"BioNTech","date":"2026-11-03","url":"https://biontechse.gcs-web.com/static-files/5248a6ea-b3c1-4985-95d4-a56e0aaa1e7a"}],"images":[{"alt":"Figure 1｜Blocking immune and vascular signals","url":"https://drugnews.com.tw/assets/articles/pd1-vegf-challengers-evidence-en/figure-01.png"},{"alt":"Figure 2｜Comparing the challengers' trial designs","url":"https://drugnews.com.tw/assets/articles/pd1-vegf-challengers-evidence-en/figure-02.png"},{"alt":"Figure 3｜Follow-up and analysis come after enrollment","url":"https://drugnews.com.tw/assets/articles/pd1-vegf-challengers-evidence-en/figure-03.png"},{"alt":"Figure 4｜AP505's development position in Taiwan","url":"https://drugnews.com.tw/assets/articles/pd1-vegf-challengers-evidence-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pd1-vegf-challengers-evidence-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-19）。After Ivonescimab's Rejection, Pfizer Is the One Testing Survival First。https://drugnews.com.tw/articles/2026-11-19-pd1-vegf-challengers-evidence-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “As registered on 2026-11-17, both specified global first-line NSCLC programs track OS: Pfizer makes it primary and BioNTech/BMS secondary”?","a":"As registered on 2026-11-17, both specified global first-line NSCLC programs track OS: Pfizer makes it primary and BioNTech/BMS secondary; this establishes no efficacy or approval ranking."},{"q":"What are the key developments in “Endpoints and populations define the comparison”?","a":"Endpoints and populations define the comparison."},{"q":"What are the key developments in “Contract ceilings differ from verified payments”?","a":"Contract ceilings differ from verified payments."}]}